Conagen develops high-purity non-GMO sulforaphane by bioconversion
Retrieved on:
Tuesday, November 29, 2022
Bedford, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Expanding on its portfolio of innovative nutritional products through biotechnology, Conagen , announced the development of its 99% high-purity sulforaphane.
Key Points:
- Bedford, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Expanding on its portfolio of innovative nutritional products through biotechnology, Conagen , announced the development of its 99% high-purity sulforaphane.
- Made by a proprietary bioconversion technology, the company plans to begin the commercialization path in 2023.
- Conagens bioconversion methods enable the production of sustainable products from many naturally occurring compounds regardless of rarity or small quantities occurring in nature.
- Sulforaphane has been associated with supporting health benefits against cancer, diabetes, digestion, and heart disease and promoting cognition.